Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781306 | 1.00 | ALDH1A1 (0.40) | ALDH1A1MAPTTDP1KDM4EMEN1 | |
| SCHEMBL27768928 | 0.83 | VCAM1 (0.40) | ALDH1A1MAPTTDP1KDM4EMEN1 | |
| SCHEMBL29719028 | 0.83 | EGFR (0.41) | ALDH1A1MAPTTDP1KDM4EMEN1 | |
| SCHEMBL25409 | 0.83 | EGFR (0.41) | ALDH1A1MAPTTDP1KDM4EMEN1 | |
| SCHEMBL156334 | 0.81 | MAP4K4 (0.43) | ALDH1A1MAPTTDP1VCAM1ATM | |
| Hydrochloric Acid SCHEMBL4781507 | 0.81 | EGFR (0.40) | ALDH1A1MAPTTDP1KDM4EMEN1 | |
| SCHEMBL17538470 | 0.81 | MAPT (0.40) | ALDH1A1MAPTTDP1KDM4EMEN1 | |
| SCHEMBL30420453 | 0.81 | MAP4K4 (0.43) | ALDH1A1MAPTTDP1VCAM1ATM | |
| SCHEMBL22983920 | 0.81 | ABCG2 (0.38) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL16212173 | 0.81 | EGFR (0.40) | ALDH1A1MAPTTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121434-A | Preparation method of high-purity quinazoline drug intermediate | 精华制药集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-104910140-A | Quinazoline compound, preparation method and application thereof | QILU PHARMACEUTICAL CO LTD | 2015-09-16 | — | — | CN | claimed |
| CN-103965175-A | 4-(substituted phenylamino)quinazoline compounds, and preparation method and application thereof | QILU PHARMACEUTICAL CO LTD | 2014-08-06 | — | — | CN | claimed |
| CN-103073539-A | 4-(substituted phenylamino)quinazoline derivative, and preparation method, pharmaceutical composition and application thereof | QILU PHARMACEUTICAL CO LTD | 2013-05-01 | — | — | CN | claimed |
| CN-102731485-A | 4-(substituted phenylamino)quinazoline derivative, its preparation method, pharmaceutical composition and application | QILU PHARMACEUTICAL CO LTD | 2012-10-17 | — | — | CN | claimed |
| CN-102702115-A | Synthetic method of 4-chloro-7-fluoro-6-nitro quinazoline | SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-03 | — | — | CN | claimed |
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119970743-A | Pharmaceutical use of tyrosine kinase inhibitors | 江苏康可得生物技术股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119390683-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-114394942-B | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
| EP-1957468-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4 - (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | T.K. Signal Ltd. (IL) | 2008-08-20 | — | — | EP | disclosed |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | T.K. SIGNAL LTD. (IL) | 2008-03-06 | — | — | US | disclosed |
| WO-2007029251-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4- (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GR0WTH FACT0R RECEPTOR TYROSINE KINASE | T.K. SIGNAL LTD. (IL) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | EGFR, TK1, ERBB2 | ALDH1A1 2098/4885MAPT 2460/4885TDP1 437/4885 |
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | ALDH1A1 769/4885MAPT 4455/4885TDP1 951/4885 |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | ALDH1A1 2177/4885MAPT 4215/4885TDP1 1178/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | ALDH1A1 363/4885MAPT 4818/4885TDP1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.